[203Pb]Pb-PSV359

N/A

Report date: 2025/11/20 13:28:36

NME

Base Information

Drug Name[203Pb]Pb-PSV359

Drug Alias Name[203Pb]Pb-PSV359[203Pb]-PSV359

ClassificationRadiation-emitting products > Nuclides > Lead > 203PbRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionFibroblast activation protein alpha modulators

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsHead and Neck NeoplasmsOvarian NeoplasmsStomach Neoplasms +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesPerspective Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesPerspective Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsHead and Neck NeoplasmsOvarian NeoplasmsStomach Neoplasms +[8]

Inactive IndicationsN/A

Other Information

ATC CodeN/A